Literature DB >> 31218441

A new 4-(pyridinyl)-4H-benzo[g]chromene-5,10-dione ruthenium(II) complex inducing senescence in 518A2 melanoma cells.

Madeleine Gold1, Yusufi Mujahid2, Khursheed Ahmed2, Hana Kostrhunova3, Jana Kasparkova3,4, Viktor Brabec3, Bernhard Biersack1, Rainer Schobert5.   

Abstract

2-Amino-5,10-dihydro-5,10-dioxo-4(pyridine-3-yl)-4H-benzo[g]chromene-3-carbonitrile 5, a cytotoxic lawsone derivative, was reacted with [Ru(p-cymene)Cl2]2 to afford a new Ru(II) 'piano-stool' complex 6 which differed from its ligand 5 by a greater selectivity for highly invasive 518A2 melanoma cells over human dermal fibroblasts in MTT cytotoxicity assays, and by inducing senescence rather than apoptosis in the former. DNA is a likely cellular target of complex 6 as it bound, presumably non-covalently, to linear and circular double-stranded DNA in vitro and as ruthenium was found in the lysate of nuclei of treated 518A2 melanoma cells. It also caused a fivefold increase of reactive oxygen species in these cells, originating from a more persistent redox cycling as visualised by cyclic voltammetry.

Entities:  

Keywords:  Anticancer agents; Lawsone; Melanoma; Naphthoquinone; Ruthenium(II) complex; Senescence

Mesh:

Substances:

Year:  2019        PMID: 31218441     DOI: 10.1007/s00775-019-01677-y

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  40 in total

Review 1.  Anticancer Activity and Modes of Action of (arene) ruthenium(II) Complexes Coordinated to C-, N-, and O-ligands.

Authors:  Bernhard Biersack
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 2.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

Review 3.  Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

Authors:  Sreekanth Thota; Daniel A Rodrigues; Debbie C Crans; Eliezer J Barreiro
Journal:  J Med Chem       Date:  2018-02-26       Impact factor: 7.446

4.  (Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells.

Authors:  B Biersack; M Zoldakova; K Effenberger; R Schobert
Journal:  Eur J Med Chem       Date:  2010-01-28       Impact factor: 6.514

5.  New (arene)ruthenium(II) complexes of 4‑aryl‑4H‑naphthopyrans with anticancer and anti-vascular activities.

Authors:  Florian Schmitt; Jana Kasparkova; Viktor Brabec; Gerrit Begemann; Rainer Schobert; Bernhard Biersack
Journal:  J Inorg Biochem       Date:  2018-04-05       Impact factor: 4.155

6.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Authors:  Claus Garbe; Ketty Peris; Axel Hauschild; Philippe Saiag; Mark Middleton; Lars Bastholt; Jean-Jacques Grob; Josep Malvehy; Julia Newton-Bishop; Alexander J Stratigos; Hubert Pehamberger; Alexander M Eggermont
Journal:  Eur J Cancer       Date:  2016-06-29       Impact factor: 9.162

7.  A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

Authors:  Jeany M Rademaker-Lakhai; Desiree van den Bongard; Dick Pluim; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

Review 8.  KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.

Authors:  Christian G Hartinger; Michael A Jakupec; Stefanie Zorbas-Seifried; Michael Groessl; Alexander Egger; Walter Berger; Haralabos Zorbas; Paul J Dyson; Bernhard K Keppler
Journal:  Chem Biodivers       Date:  2008-10       Impact factor: 2.745

Review 9.  Systemic treatments for metastatic cutaneous melanoma.

Authors:  Sandro Pasquali; Andreas V Hadjinicolaou; Vanna Chiarion Sileni; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

10.  Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.

Authors:  Howard A Burris; Suzanne Bakewell; Johanna C Bendell; Jeffrey Infante; Suzanne F Jones; David R Spigel; Glen J Weiss; Ramesh K Ramanathan; Angela Ogden; Daniel Von Hoff
Journal:  ESMO Open       Date:  2017-02-23
View more
  1 in total

Review 1.  Curcumin: reclaiming the lost ground against cancer resistance.

Authors:  Siraj Shaikh; Javed Shaikh; Yusufi Sadia Naba; Kailas Doke; Khursheed Ahmed; Mujahid Yusufi
Journal:  Cancer Drug Resist       Date:  2021-06-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.